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INTRODUCTION
Membrane transporters in the ABC superfamily are recognized as critical determinants of drug disposition (Fromm, 2003; Chan et al., 2004 ) that transport a variety of endogenous and exogenous compounds against concentration gradients at the expense of ATP hydrolysis .
Drugs that are substrates for such membrane transporters, especially those falling into Class II-IV of the FDA's Biopharmaceutics Classification System (BCS) (Amidon et al., 1995) or the extended Biopharmaceutics Drug Disposition Classification System (BDDCS) (Wu and Benet, 2005) , require accurate analysis of their complex PK behavior to properly assess their suitability as emerging drug candidates. The use of established in vitro permeability and in situ/ex vivo models, such as perfused organs models (Xia et al., 2007) provide useful yet isolated information as to the potential impact of transporters on drug disposition. Given that drugs may be substrates for multiple transporters of overlapping function (Vlaming et al., 2009a; Lagas et al., 2010a) , whole-body animal models are required to provide a comprehensive analysis of the PKs of a drug. In this regard, the use of gene knockout animal models provide an opportunity to characterize not only how specific transporters impact drug disposition, but also may be used as a tool to examine how specific inhibitors influence drug disposition (Sikic et al., 1997) .
MTX is a folate antagonist widely-used for the treatment of different diseases that require a large therapeutic dose range (Braun and Rau, 2009) ; low doses for autoimmune diseases, such as psoriasis (Hunter et al., 1962) and rheumatoid arthritis (Weinblatt et al., 1985) , and high doses for different types of cancers, such as primary CNS lymphoma (Deangelis and Iwamoto, 2006) , acute lymphoblastic leukemia (ALL) (Chessells et al., 1987) , and other neoplastic diseases (Rizzoli et al., 1985) . Based on a number of in vitro experiments, MTX is a known substrate for numerous membrane transporters including the multidrug resistance proteins (MRP) ABC sub-family C member 2 (ABCC2/MRP2) and ABCC3/MRP3 (Assaraf, 2006) . These two transporters have a role in the hepatobiliary axis, with ABCC2 located on the apical side of bile canaliculi whereas ABCC3 is located on the basolateral surface of hepatocytes (Gerk and Vore, 2002; Scheffer et al., 2002 ). An early report revealed limited MTX biliary This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on August 12, 2011 as DOI: 10.1124 at ASPET Journals on October 20, 2017 dmd.aspetjournals.org Downloaded from DMD # 41228 6 excretion in rats lacking Abcc2 (cMOAT, canalicular multispecific oganic anion transporter), which was consistent with in vitro studies on canalicular membrane vesicles (CMV) prepared from normal and Abcc2 deficient rats (Masuda et al., 1997 (Kitamura et al., 2008; Vlaming et al., 2008 
MATERIAL AND METHODS
Animal
Three strains of male mice, C57BL/6 (wild type, WT), Abcc2 -/-and Abcc3 -/-mice (20 -30 g, age 10 -15 wk) were used in the study after confirmation of their genotype by regular polymerase chain reaction. Generation of the Abcc2 -/-or Abcc3 -/-mice was described elsewhere (Belinsky et al, 2005) . All the animals were maintained on an alternating 12 hr light/dark cycle with free access to water and rodent 
LC/MS/MS assay for MTX and 7OH-MTX
MTX and its major metabolite, 7OH-MTX, in plasma were measured using an electrospray ionization LC/MS/MS system (Applied Biosystems, API 4000) described previously (Guo et al., 2007) .
In brief, each plasma sample (10 µL) was deproteinized by a 4-fold volume of methanol containing the internal standard aminopterin (3 ng/ml). After centrifugation (14,000 rpm × 15 min), a 20 µL aliquot of the supernatant was diluted 6 times with double distilled water and mixed followed by injection of a 30 µL aliquot into the LC/MS/MS system. The chromatographic system consisted of a C18 guard cartridge time of 800 ms for each ion transition. The limit of quantitation was 1.3 ng/mL and 2.6 ng/mL for MTX and 7OH-MTX, respectively. Both intra-and inter-day precision were all less than 15% for plasma concentrations over a range of 1.3 -1021.6 ng/mL for MTX and 2.6 -2062.9 ng/mL for 7OH-MTX.
MTX concentrations in urine and feces were quantitated using the same LC/MS/MS system as for plasma. In brief, each clean urine sample obtained by centrifugation was diluted 500 times with double distilled water followed by transfer of an aliquot (10 µL) that was deproteinized by 4-fold volume of methanol containing the internal standard aminopterin (1 µg/mL). After centrifugation (14,000 rpm × 5 min), an aliquot of 10 µL of supernatant was further diluted 100 times with the mobile phase and a 5 µL aliquot was injected into the LC/MS/MS system. Each sample of feces was first homogenized in a 5% conducted based on the mean and standard deviation values from two independent groups using unpaired
RESULTS
The PK properties of MTX were assessed based on its measurement in plasma, urine and feces at IV doses of 10 mg/kg, 50 mg/kg and 200 mg/kg in WT, Abcc2 -/-and Abcc3 -/-mouse strains. MTX plasma concentration-time profiles for each strain and dose level are illustrated in Figure 1 , in which a number of differences are apparent. In general, plasma MTX concentrations were highest in the Abcc2 -/-strain followed by the WT strain and then the Abcc3 -/-strain but the magnitude of the differences was also a function of dose. Regardless of the dose and strain, renal excretion of unchanged MTX is the primary elimination pathway, always greater than biliary or metabolic. Humans also utilize renal excretion as the primary route of unchanged MTX elimination and support the use of mice as a relevant animal model for MTX's PK behavior (Balis et al., 1983) . The PK parameters are summarized in Table 1 .
Interstrain analysis
Interstrain analysis indicated a number of differences in the PK parameters. Relative to WT mice,
Abcc2
-/-mice exhibited significantly higher AUC (P < 0.01) and reduced CL (P < 0.05 for low and high doses; P < 0.01 for middle dose) values at all dose levels that are attributed to the inability of Abcc2, located on the apical membrane of bile canaliculi as well as renal proximal tubules to perform its normal excretory function. At the 50 mg/kg dose level, the mean AUC value in Abcc2 -/-mice doubled relative to WT mice, which was comparable to an earlier report that had used a different genetic background of FVB mice (Vlaming et al., 2008) . The loss of Abcc2 function, as evidenced by reduced fecal excretion of MTX, coupled to the efflux action of Abcc3 on hepatocytes led to elevated MTX plasma concentrations. These elevated plasma concentrations resulted in a significant compensatory increase in the fractional renal excretion of MTX at all dose levels (P < 0.01 at low and middle doses), which serves as the primary elimination pathway regardless of strain. Given that 7OH-MTX is also a substrate for Abcc2 (Vlaming et al., 2008) , its elevated AUC and fractional conversion to MTX (see % AUC m/p , (Vlaming et al., 2009b) . Even though compensatory clearance mechanisms of MTX in the Abcc2 -/-strain were apparent they were insufficient to match the clearance rates in WT mice.
The changes in the V d between WT and Abcc2 -/-strains were difficult to decipher. At the two lower dose levels, mean V d values were less than in the WT strain and suggested that the higher plasma MTX concentrations are unable to saturate plasma protein binding, mainly albumin (Steele et al., 1979) , as well as any apically-directed vascular pumps that limit extravascular distribution. However, at a dose of 200 mg/kg, the significantly elevated V d (P < 0.05) in Abcc2 -/-mice relative to the WT group appears to be sufficient to saturate such efflux pumps and permit MTX to distribute into tissues.
Comparison of the PK parameters in the Abcc3 -/-strain to those in the WT strain revealed a number of significant differences. Total clearances were significantly elevated in the Abcc3 -/-strain compared to the WT strain at the 10 mg/kg and 50 mg/kg dose levels (P < 0.01 at low dose; P < 0.05 at middle dose), but at the high 200 mg/kg dose level CL was decreased to less than that obtained in the high dose WT group (P < 0.01, see Table 1 ). Abcc3, being a basolateral efflux pump on hepatocytes, has a protective function for hepatocytes apparent when normal biliary excretion mechanisms, such as those for
-/-strain, are absent or compromised due to genetic manipulation, disease or saturated at high MTX doses. The enhanced elimination of MTX in the absence of Abcc3 supports a compensatory process of biliary excretion at least until these apical pumps are overwhelmed at the high 200 mg/kg dose level. This enhanced biliary elimination may be attributed to increased expression of the biliary pumps and is coupled to increased fecal excretion noted at the 50 mg/kg dose level that was also associated with reduced formation of 7OH-MTX compared to the wild-type mice (see Table 1 ). The reduced formation of 7OH-MTX is also consistent with hastened biliary excretion of this metabolite as it is also an Abcc2 substrate (Vlaming et al., 2008 The increase in the V d in the Abcc3 -/-mice at the two lower doses compared to the WT strain could be attributable to the absence of Abcc3 on the basolateral membranes of epithelial cells allowing enhanced distribution to liver, kidney, intestine, adrenals and pancreas . However, at the 200 mg/kg dose level, no further change in the V d was seen in the Abcc3 -/-group.
Intrastrain analysis
Intrastrain analysis revealed dose-dependent changes in the PK variables in each strain over the dose range of 10 -200 mg/kg (see Table 1 , Figure 2 ). WT mice exhibited an approximate 2-fold increase in CL (P < 0.05) in going from the 10 mg/kg to 50 mg/kg dose level that is indicative of MichaelisMenten kinetics are operative in biliary elimination and supported by increased fecal excretion. The activity of these low affinity-high capacity pumps plateaued at the 200 mg/kg dose as there was no change in clearance or fecal excretion from the 50 mg/kg dose level. Interestingly there was not enhanced conversion of MTX to 7OH-MTX in the WT strain, and at the high 200 mg/kg dose only renal excretion appeared as a compensatory mechanism. Dose-dependent elevation in V d (P < 0.05) indicative of enhanced tissue distribution in the WT group at the 200 mg/kg dose level is consistent with saturation of the capacity of efflux pumps located at the blood-tissue interface that would be more likely when expression of such pumps is low.
The Abcc2 -/-strain also demonstrated elevated total clearance as the dose increased from 10 mg/kg to 50 mg/kg; however the elevated biliary excretion was also supplemented by compensatory metabolism to 7OH-MTX, although the latter were insignificant (P > 0.05) amongst the three dose levels.
This article has not been copyedited and formatted. The final version may differ from this version. Finally for the Abcc3 -/-group, a 2-fold increase in total clearance was observed in going from 10 to 50 mg/kg doses that was attributed to engagement of compensatory bile efflux pumps as there was not an increase in renal excretion or 7OH-MTX conversion; however the precipitous fall in CL at the 200 mg/kg dose, without compensatory increases in metabolism or renal excretion, is suggestive of hepatotoxicity coupled to the inability of Abcc3 to perform its normal protective function in hepatocytes.
There was an absence of dose-dependent changes in V d in the Abcc3 -/-group.
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DISCUSSION
The investigation of MTX PK characteristics is of interest due to the discovery that several membrane transporters are involved in its disposition that affects not only its systemic PK properties but also pharmacologically active concentrations at the cell level that are not measured in whole animals.
Extensive studies using various in vitro and in vivo models have been carried out to determine the impact of transporters on the pharmacokinetics of MTX, which are considered important mechanisms contributing to the wide interindividual variability in patients (Xia et al., 2005; Vlaming et al., 2008 . Our studies confirm previous reports that Abcc2 and Abcc3 play an important role in the PKs of MTX and that alternative elimination pathways are available in the absence of either Abcc2 or Abcc3 (Vlaming et al., 2008; van de Wetering et al., 2007; Lagas et al., 2010 a&b) . Our studies extend these past analyses in that we completed dose-dependent MTX studies in each strain and found that depending on the strain compensatory elimination mechanisms of MTX were elicited as well as saturable PK processes.
In essence, the studies demonstrate that ABC transporters with shared substrate specificity are capable to export MTX coordinately and further that hepatic metabolism can be altered in order to maintain the organism's homeostasis, albeit with limitations.
The multiple ABC transporters that accept MTX as a substrate are categorized as low affinity high capacity transporters. Uptake experiments with membrane vesicles have demonstrated that Pglycoprotein (P-gp), MRP1-5 and Breast Cancer Resistance Protein (BCRP/ABCG2) are low affinity MTX transporters with an average K m in the millimolar range with moderate-to-high capacity with an average V max ranging from 0.2 ~ 2.9 nmol/min/mg protein (Assaraf., 2006) . When transporters of overlapping function exist it would be expected that high affinity transporters would preferentially contribute to transport and as substrate concentrations are elevated lower affinity transporters would be coordinately engaged and contribute to the overall transport rate. In the current investigation, regardless of the strain, an increase in the MTX dose from 10 mg/kg to 50 mg/kg caused an increase in total clearance that is consistent with Michaelis-Menten kinetics, and when one considers interstrain differences also suggests altered transporter capacity most likely through increased protein expression.
This article has not been copyedited and formatted. The final version may differ from this version. Depending on the background strain (FVB vs. C57BL/6) in Abcc2 -/-mice, Abcc3 and Abcc4 expression in kidney and liver ranged from no different than WT to 2-fold elevations (Chu et al., 2006; Vlaming et al., 2006) . Similar expression data is not available in the Abcc3 -/-strain, but given that this group showed the greatest compensatory increase in clearance at the 50 mg/kg dose level it suggests altered transporter expression underlies the higher elimination capacity.
The increased MTX clearance observed at the 50 mg/kg dose is accompanied by increased fecal excretion that implicates Abcg2 as a biliary excretory pump. The recent studies by Vlaming et al. (2008 Vlaming et al. ( , 2009a The 7OH-MTX metabolite is a main toxic metabolite of MTX, and in fact, in rats, it is reported to be more toxic than the parent drug at doses up to 5 g/kg for MTX (Fuskevåg et al., 2000) . Moreover, MTX-induced renal dysfunction has been associated with the precipitation of both MTX and the less soluble metabolite 7OH-MTX in acidic urine (Sand and Jacobsen, 1981; Pratt et al., 1994 This article has not been copyedited and formatted. The final version may differ from this version. 
